Anteris Strengthens Board with Veteran CFO Susan Knight and Governance Expert Stephen Denaro
Anteris Technologies appointed Susan Knight, a veteran CFO and audit committee chair, and Stephen Denaro to its Board, enhancing audit and governance expertise. Knight joins the Audit and Risk Committee through 2028 while Denaro’s Class II directorship extends to the 2026 annual meeting as the DurAVR global pivotal trial advances.
1. Board Appointment Details
Anteris Technologies appointed Susan Knight as a Class I Director with a term through the 2028 annual meeting and added her to the Audit and Risk Committee, while welcoming Stephen Denaro as a Class II Director through 2026. These appointments bolster board expertise as the PARADIGM pivotal trial for the DurAVR heart valve progresses toward U.S. and EMA licensure.
2. Susan Knight Background
Knight brings over two decades of financial leadership, having served as Board Chair at Surmodics from 2015 to 2025 and held CFO roles at MTS Systems Corporation and Honeywell. She has chaired multiple audit committees, providing deep risk oversight and financial governance.
3. Stephen Denaro Return
Denaro rejoins the Board with intimate knowledge of Anteris’ strategic priorities and prior governance achievements. His expertise in corporate strategy and regulatory affairs is expected to accelerate clinical and commercial objectives.
4. Governance Impact on DurAVR Trial
The addition of seasoned governance and financial oversight positions the Board to effectively manage funding, regulatory filings, and risk as Anteris advances its DurAVR biomimetic heart valve through global clinical trials and toward market approval.